Stock Ratings / Health Care / ABOS / dividends

IPHA (52) IVVD (30) STRO (36) TARA (43) ⌘ Pro Terminal →

Acumen Pharmaceuticals Inc. (ABOS) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is ABOS trading relative to its 50-day, 200-day, and 52-week technical levels?

ABOS last traded at $0.21 (-90.82% on volume of 68,105,161 shares), positioning the stock -91.29% below its 50-day simple moving average ($2.41) and -91.60% below its 200-day simple moving average ($2.50). Across its 52-week range of $0.21 to $3.60, ABOS sits at the 0.0% percentile with a 14-day RSI of 20.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.24).

Q: Does ABOS pay a dividend and is it safe?

Acumen Pharmaceuticals Inc. (ABOS) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$0.21 -90.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.18

Acumen Pharmaceuticals Inc. (ABOS) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $165.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ABOS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ABOS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Acumen Pharmaceuticals Inc. (NASDAQ: ABOS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.21 (-90.82% 1D, market cap $165.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ABOS ranks #582 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ABOS compare to IPHA and IVVD in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ABOS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IPHA (Innate Pharma S.A. ADS) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $167.6M) and IVVD (Invivyd Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $177.4M). Among the 5-stock peer group, ABOS leads on earnings multiple (N/A) while TARA leads on capital efficiency (-34.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ABOS?

▼

Per ABOS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001576885), Acumen Pharmaceuticals Inc. generated $0 in revenue, -$121.3M in net income, and -$115.5M in free cash flow against $122.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.18 (-16.54%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABOS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY ABOS SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 20.3 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.14-21% Next Q

Q2 (-2Q)

Grade D$1.69+17.2% Next Q

Q3 (-1Q)

Grade D$1.98-89.4% Next Q

Current

Grade D-$0.21-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ABOS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ABOS currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.41) and Max Pain ($0.22) forces dealer call-delta covering toward $3.78.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABOS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ABOS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABOS)

✓Walkthrough of ABOS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ABOS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -91.21%▼ SUPPORT BREAKDOWN

2026-10-30O $0.34H $0.35L $0.21C $0.21VOL 66.55M

RES: $3.76SUP: $1.53SMA50: $2.41SMA200: $2.50

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABOS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABOS Butterfly Map → + Track ABOS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ABOS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABOS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ABOS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABOS)

Health Care Rank #582 of 1016 ⚔️ IPHA vs ABOS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABOS vs. IPHA, IVVD, STRO, TARA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Acumen Pharmaceuticals Inc. (ABOS) ranks #582 by composite RQD confidence (38/100, grade D-) and #600 by equity capitalization ($165.6M). Within this direct 5-issuer industry benchmark cohort, ABOS leads on earnings valuation at N/A trailing P/E, while TARA leads on capital efficiency and profitability with -34.7% ROIC and — gross margin. IPHA currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with ABOS at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ABOS ACTIVE Acumen Pharmaceuticals Inc.	D-	38/100	—	—	-35.0%	-90.82%	$165.6M	Benchmark Subject
IPHA Innate Pharma S.A. ADS	D+	52/100	—	—	—	-2.67%	$167.6M	/ipha-vs-abos →
IVVD Invivyd Inc.	E	30/100	—	—	-35.0%	-3.37%	$177.4M	/ivvd-vs-abos →
STRO Sutro Biopharma Inc.	D-	36/100	—	—	-35.0%	-0.44%	$151.6M	/stro-vs-abos →
TARA Protara Therapeutics Inc.	D-	43/100	—	—	-34.7%	-1.59%	$148.9M	/tara-vs-abos →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001576885

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Acumen Pharmaceuticals Inc. (ABOS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$121.3M, operating cash flow of -$115.5M, and free cash flow of -$115.5M (-34.0% YoY). On the balance sheet, ABOS closed FY2025 with $122.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$121.3M	-$115.5M	-$115.5M	$122.8M	—
FY2024 (FY)	2024-12-31	$0	-$102.3M	-$86.2M	-$86.2M	$239.0M	—
FY2023 (FY)	2023-12-31	$0	-$52.4M	-$43.1M	-$43.1M	—	—

3. ABOS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABOS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ABOS compare to IPHA and IVVD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ABOS?

Where is ABOS trading relative to its 50-day, 200-day, and 52-week technical levels?

ABOS last traded at $0.21 (-90.82% on volume of 68,105,161 shares), positioning the stock -91.29% below its 50-day simple moving average ($2.41) and -91.60% below its 200-day simple moving average ($2.50). Across its 52-week range of $0.21 to $3.60, ABOS sits at the 0.0% percentile with a 14-day RSI of 20.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.24).

ABOS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does ABOS pay a dividend and is it safe?

Acumen Pharmaceuticals Inc. (ABOS) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: ABOS RQD Cockpit ABOS 12M Forecast ABOS Earnings & Move ABOS Dividends & DRIP ABOS Insiders & 13F ABOS Whale Options ABOS Profit Sankey ABOS News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ABOS — Acumen Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline

As of: 2026-11-02T14:24Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Acumen Pharmaceuticals Inc. (ABOS) carries a composite score of 38/100 (D- — Roarable Sell — Vulnerable Balance Sheet & Flow) at a current price of $0.21 (-90.82%). Fundamental cash generation scores 6/20 (ROIC -35.0%, FCF yield —), institutional 13F whale accumulation scores 7/20, insider conviction scores 5/20, macro regime alignment scores 10/20 (Beta 1.00), and forensic balance-sheet protection scores 10/20 (Altman Z-Score N/A, Piotroski F-Score 2/9).

Investor Implication: At current trailing P/E and current forward P/E within Biotechnology: Biological Products (No Diagnostic Substances), upside depends on sustained operating margin expansion (—) and free cash flow conversion relative to the 52-week range of $0.21 – $3.60.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), ABOS is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin —), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

ABOS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Acumen Pharmaceuticals Inc. (ABOS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ABOS Debate Forum (3) ↓

🟢 CATALYST Benzinga • 4h ago

Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday

Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.

Read Full Source ↗

🔴 RISK WATCH SeekingAlpha • 2d ago

Acumen Pharmaceuticals: Altitude-AD Failure Destroys The Investment Thesis (Rating Downgrade)

Acumen Pharmaceuticals' lead Alzheimer's drug sabirnetug failed to show clinical efficacy in the ALTITUDE-AD trial. See why ABOS stock is downgraded to a sell.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 2d ago

Postmarket Movers: After-Hours Gainers and Losers

After-hours movers: INOVIO jumped 283.0% and Glucotrack dropped 57.19%, among the largest postmarket gainers and losers.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 2d ago

Most Active Stocks on Oct. 30, 2026: Intel, ChowChow Cloud and Acumen in Focus

Most active stocks on Oct. 30, 2026 included Intel, Nokia, ChowChow Cloud, TNL Mediagene, Acumen and Alphabet, with sharp price moves and heavy volume.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 2d ago

12 Health Care Stocks Moving In Friday's After-Market Session

Gainers Inovio Pharmaceuticals (NASDAQ:INO) stock moved upwards by 292.6% to $2.37 during Friday's after-market session. The market value of their outstanding shares is at $79.8 million. Capricor Therapeutics

Read Full Source ↗

🔴 RISK WATCH Benzinga • 2d ago

Citigroup Downgrades Acumen Pharmaceuticals to Neutral, Lowers Price Target to $1

Citigroup analyst Geoff Meacham downgrades Acumen Pharmaceuticals (NASDAQ:ABOS) from Buy to Neutral and lowers the price target from $5 to $1.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 2d ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks:Stock Name Volume High Low Last Change Intel Corp.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 3d ago

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ABOS Bull vs. Bear Conversation Board — What's Your Call at $0.21?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABOS 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.18 (-14.3%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ABOS (D- • RQD 38/100) a Buy at $0.21?

Welcome to the ABOS (Acumen Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.17 (-19.0%)

Spot @ $0.21

Pump the brakes on ABOS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ABOS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Acumen Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.26 (+23.8%)

Spot @ $0.21

ABOS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ABOS, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.21 (52-wk range $0.21 - $3.60), any beat on forward guidance forces shorts and underweight funds to chase.